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DObjective: Nonischemic dilated cardiomyopathy with functional mitral regurgitation carries a poor prognosis.
Mitral valve surgery with implantation of a cardiac support device can treat mitral regurgitation and promote left
ventricular reverse remodeling. This observational study evaluates clinical and echocardiographic outcomes of
an individualized medico–surgical approach, focusing on mitral regurgitation recurrence and left ventricular re-
verse remodeling.
Methods: Sixty-nine consecutive patients with heart failure (New York Heart Association class III/IV) with
functional mitral regurgitation (grade 3þ/4þ) and left ventricular remodeling (end-diastolic volume 227  73
mL, ejection fraction 26%  8%) underwent restrictive mitral annuloplasty (median ring size 26), with
(n ¼ 41) or without (n ¼ 28) a cardiac support device and optimal postoperative medical treatment. Patients
were clinically and echocardiographically evaluated at up to 3.1 years’ median follow-up.
Results: Early mortality was 5.8%. Actuarial survival at 1, 2, and 5 years was 86%  4%, 79%  5%, and
63% 7%. New York Heart Association class improved from 3.1 0.4 to 2.0 0.5 (P<.01). Cardiac support
device implantation in addition to mitral valve surgery, applied in patients with more advanced left ventricular
remodeling, resulted in similar clinical outcome, greater left ventricular end-diastolic volume decrease (33% vs
18%; P¼ .007), and in a trend toward less recurrent mitral regurgitation of grade 2þor more (actuarial freedom
at 3 years 89%  8% vs 63%  11%; P ¼ .067).
Conclusions: An individualized medico–surgical approach to nonischemic cardiomyopathy combining restric-
tive mitral annuloplasty, cardiac support device implantation, and optimal medical management leads to favor-
able survival and improved functional status, low incidence of significant recurrent mitral regurgitation, and
sustained left ventricular reverse remodeling. (J Thorac Cardiovasc Surg 2011;142:e93-100)Congestive heart failure resulting from nonischemic dilated
cardiomyopathy with secondary functional mitral regurgi-
tation (MR) carries a poor prognosis.1-4 Medical treatment
results in a 1-year survival of 52% to 87% and a 5-year
survival of 22% to 54%,1,2,4,5 with highest survivals
presented in more recent years, probably reflecting impro-
vements in medical therapy. Nonsurgical interventions
involve cardiac resynchronization therapy (CRT)6 and car-
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The Journal of Thoracic and Cadefibrillator (ICD), often combined with CRT, improves
survival by preventing death from life-threatening arrhyth-
mias.8 Surgery is considered a third-line treatment for se-
lected patients and includes cardiac transplantation and
assist device implantation or nontransplantion surgery. In
the latter category, the use of an undersized mitral annulo-
plasty ring to cure MR and to restore the shape of the spher-
ical left ventricle (LV) to its normal ellipsoid form has been
advocated by Bach and Bolling9,10 and has been adopted by
others.11 The true benefit of this approach over nonsurgical
treatment with regard to survival has been debated.12 More
recently, external cardiac restraint or cardiac support de-
vices (CSDs), for example, the CorCap device (Acorn CV,
St Paul, Minn), have become available as additional surgi-
cal alternatives to treat nonischemic dilated cardiomyopa-
thy. In a randomized trial, survival of patients with MR
and nonischemic dilated cardiomyopathy who underwent
mitral valve surgery with concomitant CSD implantation
was similar to that of patients with mitral valve surgery
alone after 2 years (85%). Implantation of a CSD, however,
resulted in a more extensive decrease of LV volumes.13rdiovascular Surgery c Volume 142, Number 3 e93
Abbreviations and Acronyms
CRT ¼ cardiac resynchronization therapy
CSD ¼ cardiac support device
ICD ¼ internal cardioverter defibrillator
IQR ¼ interquartile range
LV ¼ left ventricle (ventricular)
MR ¼ mitral regurgitation
NYHA ¼ New York Heart Association
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DIn this study, the clinical andechocardiographic outcome is
assessedof all consecutive patientswith heart failurewho had
nonischemic dilated cardiomyopathy and underwent restric-
tive mitral annuloplasty, with (n ¼ 41) or without (n ¼ 28)
CSD implantation, in our nontransplantation surgical heart
failure treatment program. Clinical outcome includes death,
functional status, and adverse events (reoperation, readmis-
sion for heart failure). Echocardiographic examination fo-
cuses on recurrence of MR and LV reverse remodeling.
PATIENTS AND METHODS
Patient Population and Indications for Surgery
Sixty-nine consecutive patients with nonischemic dilated cardiomyopa-
thy and functional MR who underwent surgery for heart failure since the
start of our medico–surgical treatment program in August 2000 until Jan-
uary 2008 were included in this analysis, except patients with concomitant
aortic valve disease. Patients were accepted for surgery regardless of ejec-
tion fraction or mitral valve geometry (ie, tenting height, leaflet angula-
tion). Patients were in New York Heart Association (NYHA) heart
failure class III (86%) or IV; mean NYHA class was 3.1 0.4 with optimal
medical management. Mean MR grade was 3.1 0.6. Mean logistic Euro-
SCORE was 11.9  9.2 (range, 2.3–48). Seventy-four percent of patients
had at least 1 contraindication for cardiac transplantation. Patient charac-
teristics are presented in Table 1.
MRwas treatedwith a restrictive semirigid complete ring annuloplasty. A
tricuspid ring annuloplasty was performed in patients with significant tricus-
pid regurgitation (grade 2þ) or (starting in 2003)when the tricuspid annulus
diameter exceeded 40 mm or exceeded 21 mm/m2 indexed to body surface
area on transthoracic echocardiography. The use of external cardiac restraint
by a CSD started in late 2002 in patients with an LVend-diastolic diameter
exceeding 65 mm or exceeding 30 mm/m2 indexed to body surface area.
Our institution’s medical ethics committee approved this analysis of
clinical data and waived the need for individual consent.
Preoperative Clinical and Echocardiographic
Assessment
Preoperative clinical status was determined according to the NYHA cri-
teria directly before surgery. Echocardiographic evaluation consisted of
standard transthoracic examination within 5 days before surgery, including
semiquantitative grading of severity of MR and tricuspid regurgitation,14
measurement of tricuspid annulus diameter, LV end-diastolic and end-
systolic diameter, and left atrial size. LV volumes and LVejection fraction
were calculated according to Simpson’s biplane method of disks.15 Base-
line echocardiographic data are summarized in Table 1.
Operative Technique
All surgical procedures were performed via midline sternotomy with
normothermic cardiopulmonary bypass and intermittent antegrade warme94 The Journal of Thoracic and Cardiovascular Surgblood cardioplegia. In patients receiving a CSD, a CorCap CSD was im-
planted first on the beating heart with suture fixation of the device to the
dorsal base of the heart along the atrioventricular groove. At the end of
the surgical procedure, the CSD was tailored to meet the preoperative
LV dimensions measured on transesophageal echocardiography, as de-
scribed earlier.16 The mitral valve was exposed through a vertical transsep-
tal approach along the right border of the foramen ovale. Ring size
(Carpentier–Edwards Physioring; Edwards Lifesciences, Irvine, Calif)
was determined after careful measurement of the height of the anterior leaf-
let and then downsizing by 2 ring sizes (ie, size 26 when measuring 30).17
Tricuspid annuloplasty was performed with a Carpentier–Edwards Classic
(until 2003) or MC3 ring. Surgical data are summarized in Table 2.
Mitral valve repair was considered successful only if there was no resid-
ual MR and a leaflet coaptation length of at least 8 mm at the A2–P2 level
on intraoperative echocardiogram.
Postoperative Clinical and Echocardiographic
Follow-up
Transthoracic echocardiography was repeated before discharge on the
seventh postoperative day and included assessment of the same parameters
as in the preoperative examination, with the addition of mean transmitral
diastolic gradient and mitral valve area calculated on the basis of pressure
half-time. After hospital discharge, all but 3 patients were followed up in
our outpatient heart failure clinic and received standardized optimal med-
ical management, with regular echocardiographic follow-up.
Diastolic and systolic reverse remodeling at follow-up were defined as
at least 15% reduction of LVend-diastolic or end-systolic volume, respec-
tively, compared with baseline volume.
Statistical Analysis
Continuous data are expressed as mean standard deviation unless oth-
erwise stated, and they were compared using the Student t test for paired
and unpaired data when appropriate. Proportions for dichotomous data
were compared by c2 analysis with Yates’ correction. Survival and freedom
from time-related events were estimated using the Kaplan–Meier method
and analyzed using the Cox proportional hazard regression. Repeated mea-
surements were analyzed by 2–way analysis of variance. SPSS statistical
software (SPSS version 16.0.2; SPSS, Inc, Chicago, Ill) was used for cal-
culations.RESULTS
All patients underwent successful mitral valve repair.
Seventy-one percent of patients received a mitral ring
size 24 or 26. A CSD was implanted in 59% of patients,
and tricuspid ring annuloplasty was performed in 73% of
patients. Intraoperative echocardiography showed a compe-
tent mitral valve in all patients, without evidence of mitral
stenosis.Immediate Outcome
There was no intraoperative mortality. Nine (13%) pa-
tients were supported by perioperative intra-aortic balloon
counterpulsation, and 6 (9%) required temporary hemodial-
ysis, with an equal distribution among CSD and no-CSD pa-
tients. Overall early mortality (in-hospital and 30-day
mortality) was 5.8% for the entire group (no-CSD 3.6%,
n ¼ 1; CSD 7.3%, n ¼ 3; P ¼ .641). Three patients died
of circulatory failure and 1 of septicemia secondary to pul-
monary infection.ery c September 2011
TABLE 1. Preoperative clinical, laboratory and echocardiographic data for all patients, and arranged by CSD status
Variable All patients Without CSD With CSD P value
No. of patients 69 28 41
Age (y) 60  12 56  14 62  10 .07
Female gender (n) 37 (54%) 19 (68%) 18 (44%) .08
NYHA class III 59 (86%) 26 (93%) 33 (80%) .18
NYHA class IV 10 (14%) 2 (7%) 8 (20%) .18
Logistic EuroSCORE 11.9  9.2 10.8  7.2 12.7  10.2 >.2
Diabetes 16 (23%) 7 (25%) 9 (22%) >.2
Chronic obstructive pulmonary disease 12 (17%) 5 (18%) 7 (17%) >.2
Atrial fibrillation 18 (26%) 6 (21%) 12 (29%) >.2
ICD before surgery 12 (17%) 3 (11%) 9 (22%) >.2
CRT before surgery 8 (12%) 2 (7%) 6 (15%) >.2
ACE inhibitor or AT2 receptor
antagonist therapy
62 (90%) 24 (86%) 38 (93%) >.2
Beta-blocker therapy 54 (78%) 22 (79%) 32 (79%) >.2
Diuretic therapy 64 (93%) 25 (91%) 39 (95%) >.2
Spironolactone therapy 35 (51%) 17 (62%) 18 (44%) >.2
Systolic blood pressure (mm Hg) 115  17 122  19 113  15 .09
Pulmonary hypertension 27 (40%) 10 (36%) 17 (41%) >.2
Creatinin (mmol/L) 110  42 120  50 103  35 .17
Plasma sodium (mmol/L) 140  4 140  5 140  4 >.2
Mitral regurgitation grade
Grade 2þ 8 3 5
Grade 3þ 45 19 26
Grade 4þ 16 6 10
LV end-diastolic diameter (mm) 67  9 65  11 69  7 .07
LV end-systolic diameter (mm) 60  10 57  12 63  7 .03
LV end-diastolic volume (mL) 227  73 201  80 245  63 .02
indexed to BSA (mL/m2) 118  38 108  39 133  32 .009
LV end-systolic volume (mL) 171  65 150  71 186  57 .03
LV ejection fraction (%) 26  8 28  9 25  8 .13
Left atrial diameter (mm) 46  8 45  10 47  6 >.2
Mean transtricuspid pressure gradient (mm Hg) 31  10 30  9 31  11 >.2
CSD,Cardiac support device; NYHA,NewYork Heart Association; ICD, internal cardioverter defibrillator; CRT, cardiac resynchronization therapy; ACE, angiotensin-converting
enzyme; AT2, angiotensin II type 2; LV, left ventricular; BSA, body surface area. P values given for comparison between patients with and without CSD.
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DTwenty-two (34%) patientswere scheduled preoperatively
to receive CRT–ICD therapy, which was realized within 1
week after surgery during the same admission period.Survival
Clinical follow-up was complete for the remaining 65
patients. Median follow-up was 3.1 years (interquartileTABLE 2. Surgical and early postoperative data for all patients, and arra
Variable All patients
CPB time (min) 132  33
Aortic crossclamp time (min) 73  22
Median mitral annuloplasty ring size (range) 26 (24–30)
Ring size 24 (n) 28 (41%)
Ring size 26 (n) 21 (30%)
Tricuspid valve annuloplasty (n) 50 (73%)
Median postoperative ventilator assist (d; range) 0.5 (0.5–40)
Median postoperative ICU stay (d; range) 2 (1–49)
Median postoperative hospital stay (d; range) 12 (6–80)
CSD, Cardiac support device; CPB, cardiopulmonary bypass; ICU, intensive care unit. P
The Journal of Thoracic and Carange [IQR], 1.4–4.1 years). For the no-CSD group it was
4.3 years (IQR, 1.9–5.8 years) and for the CSD group it
was 2.4 years (IQR, 1.3–4.0 years).
There were 18 late deaths during follow-up (no-CSD, 12;
CSD, 6), with 50% of deaths resulting from cardiac causes.
Overall survival (Kaplan–Meier estimate) at 1 year, 2 years,
and 5 years was 86%  4%, 79%  5%, and 63%  7%,nged by CSD status
Without CSD With CSD P value
126  25 136  36 >.2
74  18 72  24 >.2
26 (24–30) 26 (24–30) >.2
11 (40%) 17 (42%) >.2
8 (29%) 13 (32%) >.2
16 (57%) 34 (83%) .04
1 (0.5–40) 0.5 (0.5–10) >.2
3 (1–49) 2 (1–24) >.2
12 (5–80) 12 (5–30) >.2
values given for comparison between patients with and without CSD.
rdiovascular Surgery c Volume 142, Number 3 e95
FIGURE 1. A, Survival estimated by Kaplan–Meier method for all patients. B, Survival estimated by Kaplan–Meier method for cohorts with and without
a cardiac support device (CSD). Patients at risk per cohort are shown under the horizontal axis (CSD presented in boldface; no-CSD in regular type). HR,
Hazard ratio; CI, confidence intervals.
FIGURE 2. Clinical status according to New York Heart Association
(NYHA) criteria at baseline and at late follow-up.
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centages were 86%  7%, 75%  8%, and 55%  10%,
respectively, versus 85%  6%, 82%  6%, and 74% 
8% for the CSD group, without significant difference
(Figure 1, B).
Adverse Events
Thirteen (20%) patients were readmitted for heart fail-
ure. The incidence of hospital readmissions for heart failure
was 1 per 5.84 patient-years (38 readmissions in 222.3
patient-years). Eight (62%) of these 13 patients died during
follow-up (mean interval between first readmission and
death, 8months; range 1–17months), and 1 is on the cardiac
transplantation waiting list.
Eleven patients received CRT/ICD therapy during
follow-up. Of 42 patients with ICD registration analysis,
24 (57%) had at least 1 episode of ventricular tachycardia,
of whom 14 had sustained ventricular tachycardia requiring
antitachycardia pacing or shock (n ¼ 3). Two patients had
successful shock therapy for ventricular fibrillation.
There were 3 cases of partial mitral ring dehiscence. One
patient (CSD group) underwent successful refixation 2
months after the initial operation. Two other patients (with-
out CSD) did not have reoperation; 1 had malignant disease,
and the other declined redo surgery. Two patients had an is-
chemic cerebrovascular accident (1 fatal and the other with
complete recovery), and another patient had a peripheral
arterial embolism.
Long-Term Clinical Outcome
For long-term survivors, mean NYHA class improved
from 3.1 0.4 to 2.0 0.5 (P<.01), with 5 (11%) patientse96 The Journal of Thoracic and Cardiovascular Surgin NYHA class III, with similar results in the CSD and no-
CSD groups. Forty-three (91%) surviving patients experi-
enced improvement of symptoms (Figure 2).Echocardiographic Outcome
Echocardiographic follow-up for hospital survivors was
available for all but 3 patients (95% complete). Mean late
echocardiographic follow-up time was 2.3  1.4 years
(IQR 1.0–3.5) and was similar for the CSD and no-CSD
groups (2.2  1.4 years and 2.6  1.4 years, respectively).
Echocardiographic data, summarized in Table 3, also in-
clude results in patients who died during follow-up.ery c September 2011
TABLE 3. Echocardiographic parameters for all patients with available complete preoperative, early postoperative, and long-term follow-up data
Variable Preoperatively Early postoperatively Long-term follow-up
MR grade
None — 53 30
Grade 1þ — 15 22
Grade 2þ 8 — 7
Grade 3þ 45 — 2
Grade 4þ 16 — 1
LV end-diastolic diameter (mm) 68  9 63  9* 60  11*
LV end-systolic diameter (mm) 61  10 56  10* 54  12*
LV end-diastolic volume (mL) 227  73 205  72* 161  63*y
LV end-systolic volume (mL) 171  65 153  66* 116  55*y
LV ejection fraction (%) 26  8 25  8 29  11
Left atrial diameter (mm) 46  8 44  8* 44  8*
Mean transmitral diastolic gradient (mm Hg) 1.8 0.9 4.0  1.3* 3.6  1.8*
Mitral valve area (cm2) 3.8  1.2 3.3  0.8 3.0  1.0*
Mean transtricuspid pressure gradient (mm Hg) 33  10 24  8* 28  10*
MR, Mitral regurgitation; LV, left ventricular. *P<.001 versus preoperative echocardiography. yP<.001 versus early postoperative echocardiography.
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rather than being the consequence of attrition through
death.
MR and Stenosis
MR decreased significantly at early postoperative and
late follow-up. At late follow-up, 16% of patients had
MR grade 2þor more. In the no-CSD group this percentage
was 28% versus 8.3% in the CSD group. Actuarial freedom
from recurrent MR of grade 2þor more at 3 years is 89%
8% in the CSD group versus 63%  11% in the no-CSD
group (P ¼ .067). Cox regression analysis did not reveal
any predictors for recurrence of MR (forcing CSD implan-
tation, CRT/ICD therapy, and LV end-diastolic volume at
baseline into the model). Sixty percent of patients who
had recurrent MR died during follow-up. Mean transmitral
gradient was elevated (>5 mm Hg) in 3 (5%) patients.
LV Reverse Remodeling and Function
LV volumes decreased over time (Figure 3). Initial reduc-
tion of volumes (from preoperatively to early postopera-
tively) was similar in both groups. At late follow-up,
a higher decrease was observed in the CSD group: mean
LV end-diastolic volume reduction was 82 mL versus
39 mL, or 33% vs 18% (P ¼ .007). LV end-systolic vol-
ume reduction was66 mL versus34 mL, or 34% versus
20% (P ¼ .042). Whereas baseline volumes in the CSD
group were significantly higher, the values at late follow-
up did not differ between the 2 groups. Two-way analysis
of variance showed that the difference in magnitude of re-
verse remodeling comparing the CSD and no-CSD groups
is statistically significant; linear regression indicated that
both implantation of CSD (P¼ .041) and end-diastolic vol-
ume at baseline (P<.001) were determinants of final end-
diastolic volume, with the effect of CSD implantation beingThe Journal of Thoracic and Caindependent of initial end-diastolic volume (interaction var-
iable P¼ .658). Diastolic reverse remodeling at late follow-
up was present in 76% of patients (CSD, 88%; no-CSD,
61%), and systolic reverse remodeling occurred in 73%
(CSD, 81%; no-CSD, 61%). LVejection fraction increased
from 29%  8% to 30%  7% in the no-CSD group
(P ¼ .426) and from 25%  8% to 29%  13% in the
CSD group (P ¼ .123).
Comparison Between Survivors and Nonsurvivors
There were no differences between survivors and nonsur-
vivors with regard to preoperative demographics, medical
treatment, laboratory values, or baseline echocardiographic
characteristics. Although survivors had relatively more
often CRT/ICD therapy (77% vs 44%) and CSD implanta-
tion (68% vs 33%), differences were not significant using
Cox regression; for CRT/ICD therapy: hazard ratio,
0.50; 95% CI, 0.16–1.55; P ¼ .228; for CSD: hazard ratio,
0.27; 95% CI, 0.26–1.45; P ¼ .267.
COMMENT
This study describes the long-term clinical and echocar-
diographic outcome of a nontransplantion medico–surgical
treatment program in a consecutive series of patients with
nonischemic dilated cardiomyopathy and functional MR,
with moderately severe or severe congestive heart failure de-
spite optimal medical treatment. The main findings of this
study are as follows: (1) mitral valve repair with a restrictive
mitral annuloplasty with or without external LV constraint
using a CSD leads to improvement of functional status and
a favorable long-term survival; (2) restrictive mitral annulo-
plasty, with or without external LV constraint, leads to a low
incidence of significant recurrent MR and to reverse LV re-
modeling in a vast majority of patients, which is sustained
at long-term follow-up; (3) additional CSD implantation inrdiovascular Surgery c Volume 142, Number 3 e97
FIGURE 3. Left panel: Evolution of left ventricular end-diastolic volumes (LVEDV) preoperatively, at early postoperative follow-up, and at long-term
follow-up in patients with a cardiac support device (CSDþ, solid line) and without a cardiac support device (CSD, interrupted line). P value given for
2-way analysis of variance for repeated measurements, comparing between subjects effects with CSD as a factor. Significant value indicates a difference
in development of volumes over time between both groups. Comparisons within groups for volumes at different times were performed with Bonferroni post-
hoc comparisons and indicated as follows: *P<.01 versus preoperative, yP<.01 versus early postoperative echocardiogram. Right panel: Similarly, evo-
lution of left ventricular end-systolic volumes (LVESV) throughout the follow-up.
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LV volume reduction, resulting in similar LV end-diastolic
volumes at late follow-up comparing patients with and with-
out CSD; and (4) CSD implantation shows a trend toward
a lower incidence of recurrent MR.
The treatment strategies presented result from an ongoing
conceptualization, implementation, and evaluation of indi-
vidualized surgical and nonsurgical interventions in patients
with heart failure. The surgical mainstay of this approach is
the treatment of functional MR as described by Bach and
Bolling,9,10 with a consistent and reproducible technique:
implantation of a (semi-)rigid complete mitral annuloplasty
ring using stringent downsizing by 2 ring sizes. In patients
with ischemic cardiomyopathy and preoperative LV end-
diastolic dimension of 65 mm or less, this strategy provides
good clinical outcome, absence of significant recurrent
MR, and sustained LV reverse remodeling, but in patients
with more extensive LV remodeling results remain
poor.17,18 This finding initiated the use of external cardiac
constraint with a CorCap CSD in patients with heart failure
who had an LV end-diastolic dimension greater than 65
mm or greater than 30 mm/m2 indexed to body surface
area, starting November 2002. Another strategy change in-
volved the extended indication for a tricuspid ring annulo-
plasty in patients with annular dilatation (diameter on
transthoracic echocardiography>40 mm) from September
2003 onward, initiated by the results of Dreyfus and associ-
ates.19 Patients with an LV ejection fraction less than 30%
to 35% receive ICD therapy to lower the risk of sudden car-
diac death since the results of the DEFINITE trial8 became
available, whereas CRT is used as an adjuvant therapy to
address mechanical and electrical dyssynchrony after the
results of the CARE-HF trial.6
It is impossible to distinguish the separate effects of phar-
macologic therapy, CRT/ICD therapy, cardiac rehabilita-
tion, and all different surgical interventions on survival,
MR, and LV reverse remodeling. However, a critical ap-e98 The Journal of Thoracic and Cardiovascular Surgpraisal of what is known in the literature regarding the ef-
fects of these different treatment modalities is necessary
to put the conclusions of the current study into perspective.
Studies on Surgical Treatment of Nonischemic
Cardiomyopathy
Outcome data for surgical treatment of nonischemic car-
diomyopathy are scarce, andmost studies combine ischemic
and nonischemic causes. Bolling10 presented the cases of
140 patients with end-stage heart failure, of whom two
thirds had a nonischemic etiology. Patients had low ejection
fraction (16%) and increased LV end-diastolic volume
(281mL). All patients received an undersizedmitral ring an-
nuloplasty. The series from Gummert and colleagues11 in-
cludes 53 patients with nonischemic cardiomyopathy who
received an undersized mitral ring annuloplasty (median
ring size 28). Mean ejection fraction was 25%, and LV
end-diastolic dimension was 69 mm. In the Acorn trial,13
300 patients (90% nonischemic cardiomyopathy) were ran-
domized either to mitral valve surgery with or without CSD
or to medical therapy with or without CSD. Patients were in
NYHA class II to IV with a 24% LVejection fraction (up to
45%) and an LVend-diastolic volume of 270 100mL. For
comparison, our study involves 69 patients with only noni-
schemic cardiomyopathy, NYHA class III/IV, ejection frac-
tion 26% 8%, and LVend-diastolic volume 227 73mL.
Effects on Survival and Functional Status
Early mortality in the present study (5.8%) is comparable
with that in the series of Bolling10 (6%) and Gummert and
associates11 (6.1%), but higher than reported in the Acorn
trial (1.6%),13 which however also includes patients with
less severe heart failure (23% of patients in NYHA class
II and 41% of patients with MR grade 2þ). Our long-term
actuarial survival in the no-CSD group equals that of Bol-
ling10 (52% at 5 years vs 55% in the current study); Gum-
mert and associates11 report a crude mortality of 25% and 7ery c September 2011
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tality in the Acorn trial was 26% at 3 years, without differ-
ences between CSD and no-CSD groups,20 as also noted in
our study. Actuarial 5-year survival for the CSD group in the
current study (74%  8%) cannot be compared with other
studies.
The beneficial effect of mitral valve surgery for func-
tional MR on survival has been debated by Wu and associ-
ates12 in a study reflecting data from 1995 to 2002, when
this type of surgery was emerging. Wu’s group uses propen-
sity analysis to compare event-free survival (freedom from
death, LVassist device implantation, or cardiac transplanta-
tion) between patients who underwent undersized mitral an-
nuloplasty and patients who were candidates for mitral
valve repair based on echocardiography but did not undergo
surgery. In the nonischemic group (276 patients), only 37
patients underwent mitral valve surgery. Event-free survival
is similar for surgically and medically treated patients.
However, the group not undergoing mitral valve surgery
was favored by younger age, greater likelihood of spirono-
lactone treatment, and more ICD therapy; LVejection frac-
tion was lower. In addition, no information on clinical status
of these patients is provided, no echocardiographic exami-
nations were performed, and a high likelihood of lead-
time bias favoring the nonsurgical group is present. As
such, statements on the true benefit of mitral valve surgery
over medical therapy remain speculative.
Mortality in heart failure is directly related to LV remod-
eling. In the BEST trial (Beta-blocker Evaluation of Sur-
vival), LV end-diastolic volume indexed to body surface
area exceeding 120 mL/m2 was an independent predictor
of death.21 Interestingly, in our group 51% of patients
had an indexed LV end-diastolic volume greater than
120 mL/m2 (CSD 60%; no-CSD 35%), but mortality was
similar for these 2 groups, indirectly suggesting a relative
survival benefit for patients with a more dilated LV in the
current treatment program.
Survival in our series is certainly positively influenced
by standardized optimal pharmacologic therapy and by
CRT/ICD therapy, which are mainstays of nonsurgical heart
failure treatment. CRT improves survival in patients with
NYHA class III/IV heart failure who have LV dyssyn-
chrony,6 but the high incidence of sudden death in CRT pa-
tients in the CArdiac REsynchronization–Heart Failure
(CARE-HF) trial leaves room for additional ICD therapy.22
In our series, CRT/ICD therapy was always combined.
Effects on MR and LV Reverse Remodeling
All available echocardiographic data, including those of
nonsurvivors, were analyzed, and therefore echocardio-
graphic results reflect the true effects of the combined med-
ico–surgical treatment program.
The sustained abolishment of functional MR by stringent
downsizing by 2 ring sizes using a complete semirigid ringThe Journal of Thoracic and Cahas been shown before.10,18 High MR recurrence rates in
(ischemic) patients as reported in other series might be
related to inconsistencies in patient selection and surgical
techniques.23
In the current study, patients receiving a CSD had a trend
toward a lower incidence of recurrent MR of grade 2 or
more. This effect was also found in the Acorn trial. Most
likely, the potentially beneficial effects of CSD implanta-
tion on LV volumes result from reduced tethering of the mi-
tral valve subvalvular apparatus with reduction of MR,
which in turn further decreases LV volumes.
CRT has shown a decrease in MR severity in nonische-
mic cardiomyopathy both acutely and after 1 year; effective
regurgitant orifice area decreased by 40% to 50%24,25 and
average MR jet area by 45%.26 This is explained by shorter
closing time of the mitral valve owing to improved LV con-
traction. However, the effect is highly variable between pa-
tients, and approximately 35% of patients do not show any
response.
In the current study, long-term LV reverse remodeling was
observed in 75% of patients. The magnitude of LV volume
decreasewas significantly greater in theCSDgroup: although
these patients had significantly higher LV volumes at
baseline, these differences had disappeared at late follow-up.
Bolling10 showed a 27% decrease of LV end-diastolic
volume at 2 years by mitral valve repair alone. In our series,
LVend-diastolic volume decreased by 18% after mitral re-
pair only and by 35% after CSD implantation.
In the Acorn trial at 2.3 years, LV end-diastolic volume
after mitral valve surgery decreased by only 17% compared
with 24% in the mitral valve surgery plus CSD group.
These effects appeared 3 to 6 months after surgery and
were maintained thereafter.
It is reasonable to expect that the initial drop of LV vol-
umes results from the abrupt decrease in LV volume over-
load after restoration of mitral valve competence, and that
it is independent of initial LV volume. Further decrease
(true reverse remodeling), however, is probably the conse-
quence of changes at a cellular level that are intuitively
more likely to occur in less dilated ventricles. Therefore,
we believe that the progressive LV volume decrease in the
CSD group, leading to similar LV end-diastolic volumes
at late follow-up, reflects a true beneficial effect of the CSD.
The effect of CRT on LV reverse remodeling was evalu-
ated in the CARE-HF trial.27 It appeared between 3 and 9
months after initiation and was sustained at 29 months; at
that time, LV end-diastolic volume had decreased by 19%
and end-systolic volume by 26%. Forty-nine percent of pa-
tients showed at least 15% volume reduction at 18 months’
follow-up, as compared with 19% in the medically treated
group.
In conclusion, an individualized combined medical and
surgical approach to patients with congestive heart failure
of nonischemic etiology and MR that includes standardizedrdiovascular Surgery c Volume 142, Number 3 e99
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Dpharmacologic treatment, CRT/ICD therapy, consistent re-
strictive mitral annuloplasty surgery in all patients, and
CSD implantation in patients with advanced LV remodeling
leads to favorable survival, clinical improvement, low inci-
dence of significant recurrent MR, and sustained LV reverse
remodeling at longer follow-up. Additional CSD implanta-
tion in patients with more advanced LV remodeling leads to
greater LV volume reduction and to a tendency toward less
recurrent MR. Longer follow-up is necessary to establish
whether this can further improve survival.
STUDY LIMITATIONS
This study has an observational nature without a control
group. Patients were subjected to individualized treatments,
which have changed over time with growing knowledge,
and which were based on preoperative characteristics. By
definition, selection bias was introduced. Among 12 pa-
tients who underwent surgery before the CSD became avail-
able, 9 actually would have qualified to receive a CSD on
the basis of LV end-diastolic dimension. When these pa-
tients are left out of the analyses, the conclusions of this
study remain unchanged with regard to survival, LV reverse
remodeling, and recurrence of MR.
In addition, the lack of a control group makes it hard to
draw conclusions regarding observed differences in this
study. We would emphasize, however, that patients in the
CSD group, on the basis of their higher baseline LV vol-
umes, would be expected to have a poorer survival and
a lower chance of reverse remodeling with an associated
higher chance of recurrent MR. In this study, clinical and
echocardiographic outcomes are at least similar, indirectly
suggesting a beneficial effect of applying the CSD in these
sicker patients.References
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